Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.
Rogala P, Czarnecka AM, Cybulska-Stopa B, Ostaszewski K, Piejko K, Ziętek M, Dziura R, Rutkowska E, Galus Ł, Kempa-Kamińska N, Calik J, Sałek-Zań A, Zemełka T, Bal W, Kamycka A, Świtaj T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Rutkowski P. Rogala P, et al. Among authors: kempa kaminska n. J Clin Med. 2022 Apr 17;11(8):2239. doi: 10.3390/jcm11082239. J Clin Med. 2022. PMID: 35456332 Free PMC article.
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.
Cybulska-Stopa B, Ziętek M, Kamińska-Winciorek G, Czarnecka AM, Piejko K, Galus Ł, Ziółkowska B, Kieszko S, Kempa-Kamińska N, Calik J, Zemełka T, Kubiatowski T, Suwiński R, Mackiewicz J, Rutkowski P. Cybulska-Stopa B, et al. Among authors: kempa kaminska n. Melanoma Res. 2021 Feb 1;31(1):49-57. doi: 10.1097/CMR.0000000000000705. Melanoma Res. 2021. PMID: 33165240
First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.
Cybulska-Stopa B, Pacholczak-Madej R, Kamińska-Winciorek G, Ziętek M, Czarnecka AM, Piejko K, Galus Ł, Ziółkowska B, Kieszko S, Kempa-Kamińska N, Calik J, Rolski J, Sałek-Zań A, Gajewska-Wicher K, Drosik-Kwaśniewska A, Rogala P, Kubiatowski T, Suwiński R, Mackiewicz J, Rutkowski P. Cybulska-Stopa B, et al. Among authors: kempa kaminska n. Immunotherapy. 2021 Mar;13(4):297-307. doi: 10.2217/imt-2020-0217. Epub 2020 Dec 23. Immunotherapy. 2021. PMID: 33353420
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma.
Cybulska-Stopa B, Ziętek M, Czarnecka AM, Piejko K, Dziura R, Galus Ł, Ziółkowska B, Kieszko S, Kempa-Kamińska N, Calik J, Seredyńska J, Gądek K, Zemełka T, Teterycz P, Kubiatowski T, Suwiński R, Mackiewicz J, Rutkowski P. Cybulska-Stopa B, et al. Among authors: kempa kaminska n. J Dermatolog Treat. 2022 Jun;33(4):2168-2174. doi: 10.1080/09546634.2021.1937477. Epub 2021 Jun 14. J Dermatolog Treat. 2022. PMID: 34057374 Free article.
Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.
Rogala P, Czarnecka AM, Cybulska-Stopa B, Ostaszewski K, Piejko K, Ziętek M, Dziura R, Rutkowska E, Galus Ł, Kempa-Kamińska N, Seredyńska J, Bal W, Kozak K, Surus-Hyla A, Kubiatowski T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Rutkowski P. Rogala P, et al. Among authors: kempa kaminska n. Cancers (Basel). 2022 Apr 24;14(9):2123. doi: 10.3390/cancers14092123. Cancers (Basel). 2022. PMID: 35565255 Free PMC article.
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.
Piejko K, Cybulska-Stopa B, Ziętek M, Dziura R, Galus Ł, Kempa-Kamińska N, Ziółkowska B, Rutkowska E, Kopciński T, Kubiatowski T, Bal W, Suwiński R, Mackiewicz J, Kamińska-Winciorek G, Czarnecka AM, Rutkowski P. Piejko K, et al. Among authors: kempa kaminska n. Target Oncol. 2023 Mar;18(2):235-245. doi: 10.1007/s11523-023-00954-w. Epub 2023 Mar 11. Target Oncol. 2023. PMID: 36906728 Free PMC article.
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.
Cybulska-Stopa B, Piejko K, Ostaszewski K, Dziura R, Galus Ł, Ziółkowska B, Kempa-Kamińska N, Ziętek M, Bal W, Kamycka A, Dudzisz-Śledź M, Kubiatowski T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Czarnecka AM, Rutkowski P. Cybulska-Stopa B, et al. Among authors: kempa kaminska n. Melanoma Res. 2023 Jun 1;33(3):208-217. doi: 10.1097/CMR.0000000000000885. Epub 2023 Apr 3. Melanoma Res. 2023. PMID: 37015054
Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report.
Placzke J, Rosińska M, Sobczuk P, Ziętek M, Kempa-Kamińska N, Cybulska-Stopa B, Kamińska-Winciorek G, Bal W, Mackiewicz J, Galus Ł, Las-Jankowska M, Jankowski M, Dziura R, Drucis K, Borkowska A, Świtaj T, Rogala P, Kozak K, Klimczak A, Jagodzińska-Mucha P, Szumera-Ciećkiewicz A, Koseła-Paterczyk H, Rutkowski P. Placzke J, et al. Among authors: kempa kaminska n. Cancers (Basel). 2023 Sep 1;15(17):4384. doi: 10.3390/cancers15174384. Cancers (Basel). 2023. PMID: 37686659 Free PMC article.